Swimming Upstream: Comparative Effectiveness Research in the US.
- Published in:
- 2009
- By:
- Publication type:
- Opinion
Works matching IS 11707690 AND DT 2009 AND VI 27 AND IP 12
Results: 8
1
2
Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 12, p. 1005, doi. 10.2165/11314000-000000000-00000
- By:
- Publication type:
- Article
3
Weighting Must Wait: Incorporating Equity Concerns into Cost-Effectiveness Analysis May Take Longer than Expected.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 12, p. 983, doi. 10.2165/11314100-000000000-00000
- By:
- Publication type:
- Article
4
Healthcare Costs and Obesity Prevention: Drug Costs and Other Sector-Specific Consequences.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 12, p. 1031, doi. 10.2165/11319900-000000000-00000
- By:
- Publication type:
- Article
5
Cost Effectiveness of Herpes Zoster Vaccine in Canada.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 12, p. 991, doi. 10.2165/11314010-000000000-00000
- By:
- Publication type:
- Article
6
Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 12, p. 1017, doi. 10.2165/11314030-000000000-00000
- By:
- Publication type:
- Article
7
ACKNOWLEDGEMENT.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 12, p. 975
- Publication type:
- Article
8
Accounting for the Development of Antibacterial Resistance in the Cost Effectiveness of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in the UK.
- Published in:
- PharmacoEconomics, 2009, v. 27, n. 12, p. 1045, doi. 10.2165/11310080-000000000-00000
- By:
- Publication type:
- Article